カルシウム拮抗薬市場：薬剤クラス別、エンドユーザー別、流通チャネル別-2025-2030年の世界予測

カルシウム拮抗薬市場は、2023年に135億2,000万米ドルと評価され、2024年には142億5,000万米ドルに達すると予測され、CAGR 6.23％で成長し、2030年には206億4,000万米ドルに達すると予測されています。

カルシウム拮抗薬（CCBs）は、カルシウムイオンが心臓や動脈の血管平滑筋細胞に入るのを阻害することにより、主に高血圧、狭心症、特定の心臓不整脈を管理するために使用される薬剤の一種です。この阻害作用は血管の弛緩と拡張をもたらし、心血管系の治療プロトコールにおいて不可欠なものとなっています。都市化、座りがちなライフスタイル、高齢化によって心血管疾患の世界的有病率が上昇するにつれ、CCBの必要性は高まっています。CCBの用途は、高血圧管理のための医薬品処方から、くも膜下出血後の脳血管攣縮の治療に使用される製剤まで多岐にわたる。最終用途の範囲には病院、診療所、小売薬局が含まれるため、幅広い患者層が利用できます。市場成長は、心血管の健康に対する意識の高まり、薬剤製剤技術の進歩、片頭痛やレイノー現象のような他の疾患への応用拡大といった要因に大きく影響されています。新たなビジネスチャンスは、副作用が少なく、バイオアベイラビリティが改善され、他の心血管治療薬との適合性が高いCCBの開発にあります。しかし、潜在的な副作用、厳しい規制当局の承認、ジェネリック医薬品の人気の高まりといった課題によって、市場の成長は抑制されています。イノベーションの余地は、個別化医療や、患者のアドヒアランスと転帰を高めるためのデジタルヘルス技術の統合といった分野で熟しています。企業は、有効性と患者体験を向上させる新しいドラッグデリバリーシステムを探求する研究に投資することで、利益を得ることができます。CCB市場は、絶え間ない競争と技術革新の圧力を特徴とするダイナミックな性質を示します。市場シェアの拡大を目指す企業は、包括的な市場分析、戦略的パートナーシップ、強力な研究開発投資を重視し、急速に進化する市場で優位に立つ必要があります。

市場力学：急速に進化するカルシウム拮抗薬市場の主要市場インサイトを公開

カルシウム拮抗薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の低血圧患者の増加
  • 疾患の早期診断・治療への傾倒
  • 低血圧治療に対する意識の高まり
• 市場抑制要因
  • 製品のリコール、原材料コストの変動
• 市場機会
  • 新世代のカルシウム拮抗薬のイントロダクション
  • カルシウム拮抗薬の有効性を検証するための臨床試験
• 市場の課題
  • カルシウム拮抗薬に関連する副作用

ポーターの5つの力：カルシウム拮抗薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、カルシウム拮抗薬市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：カルシウム拮抗薬市場における外部からの影響の把握

外部マクロ環境要因は、カルシウム拮抗薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析カルシウム拮抗薬市場における競合情勢の把握

カルシウム拮抗薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的な意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスカルシウム拮抗薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、カルシウム拮抗薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨カルシウム拮抗薬市場における成功への道筋を描く

カルシウム拮抗薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報に基づいた意思決定を行う上で役立つ重要な質問にも回答しています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で低血圧の発生率が上昇
    • 病気の早期診断と治療への傾向
    • 低血圧治療に関する意識の向上
  • 抑制要因
    • 製品リコールと原材料費の変動
  • 機会
    • 新世代カルシウム拮抗薬のイントロダクション
    • カルシウム拮抗薬の有効性をテストするための臨床試験
  • 課題
    • カルシウム拮抗薬に関連する悪影響
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 カルシウム拮抗薬市場薬剤クラス別

• ベンゾジアゼピン
• ジヒドロピリジン
• フェニルアルキルアミン

第7章 カルシウム拮抗薬市場：エンドユーザー別

• ホームケア
• 病院
• 専門クリニック

第8章 カルシウム拮抗薬市場：流通チャネル別

• 病院薬局
• オンライン薬局
• 小売薬局

第9章 南北アメリカのカルシウム拮抗薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域のカルシウム拮抗薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのカルシウム拮抗薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Apotex Inc.
• Astellas Pharma Inc.
• AstraZeneca PLC
• Bausch Health Companies Inc.
• Bayer AG
• Boehringer Ingelheim International GmbH
• Bristol Myers Squibb Company
• Cadila Pharmaceuticals Limited
• Daiichi Sankyo Company, Limited
• Dr. Reddy's Laboratories Ltd.
• Glenmark Pharmaceuticals U.S. Inc.
• Hikma Pharmaceuticals PLC
• INTAS PHARMACEUTICALS LTD.
• Kyowa Kirin Co., Ltd.
• Lupin Pharmaceuticals, Inc.
• Merck & Co., Inc.
• Novartis AG
• OTSUKA PHARMACEUTICAL CO., LTD.
• Pfizer Inc.
• Sanofi S.A.
• Sun Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

• FIGURE 1. CALCIUM CHANNEL BLOCKERS MARKET RESEARCH PROCESS
• FIGURE 2. CALCIUM CHANNEL BLOCKERS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL CALCIUM CHANNEL BLOCKERS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. CALCIUM CHANNEL BLOCKERS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. CALCIUM CHANNEL BLOCKERS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CALCIUM CHANNEL BLOCKERS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CALCIUM CHANNEL BLOCKERS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CALCIUM CHANNEL BLOCKERS MARKET DYNAMICS
• TABLE 7. GLOBAL CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY BENZODIAZEPINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DIHYDROPYRIDINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY PHENYLALKYLAMINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 29. CANADA CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 30. CANADA CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 31. CANADA CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 46. CHINA CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 47. CHINA CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 48. CHINA CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 49. INDIA CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 50. INDIA CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 51. INDIA CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 101. ITALY CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 102. ITALY CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 103. ITALY CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 113. POLAND CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 114. POLAND CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 115. POLAND CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 116. QATAR CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 117. QATAR CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 118. QATAR CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 146. CALCIUM CHANNEL BLOCKERS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 147. CALCIUM CHANNEL BLOCKERS MARKET, FPNV POSITIONING MATRIX, 2023

The Calcium Channel Blockers Market was valued at USD 13.52 billion in 2023, expected to reach USD 14.25 billion in 2024, and is projected to grow at a CAGR of 6.23%, to USD 20.64 billion by 2030.

Calcium Channel Blockers (CCBs) are a class of medications used primarily to manage hypertension, angina, and certain heart arrhythmias by inhibiting calcium ions from entering cardiac and arterial vascular smooth muscle cells. This blockade results in relaxation and dilation of blood vessels, making them essential in cardiovascular treatment protocols. The scope of CCBs extends beyond traditional uses, as their necessity increases with the rising global prevalence of cardiovascular diseases due to urbanization, sedentary lifestyles, and aging populations. The application niche for CCBs spans from pharmaceutical prescriptions for high blood pressure management to formulations used in treating cerebral vasospasm post-subarachnoid hemorrhage. The end-use scope includes hospitals, clinics, and retail pharmacies, making them accessible to a broad patient demographic. Market growth is significantly influenced by factors such as increasing awareness of cardiovascular health, advancements in drug formulation technologies, and expanded applications in other diseases like migraines and Raynaud's phenomenon. An emerging opportunity lies in the development of CCBs with fewer side effects, improved bioavailability, and compatibility with other cardiovascular drugs. However, market growth is curtailed by challenges such as potential side effects, strict regulatory approvals, and the rising popularity of generic alternatives. The scope for innovation is ripe in areas such as personalized medicine and the integration of digital health technologies to enhance patient adherence and outcomes. Companies stand to gain by investing in research exploring novel drug delivery systems that enhance efficacy and patient experience. The CCB market exhibits a dynamic nature characterized by constant competition and innovation pressure. Players seeking substantial market share should emphasize comprehensive market analyses, strategic partnerships, and robust R&D investments to stay ahead in the rapidly evolving landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Calcium Channel Blockers Market

The Calcium Channel Blockers Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising incidences of low blood pressure worldwide
  • Inclination toward early diagnosis and treatment of diseases
  • Increasing awareness regarding low blood pressure treatments
• Market Restraints
  • Product recall and volatility in raw material cost
• Market Opportunities
  • Introduction of new generation calcium channel blockers
  • Clinical trials to test the efficacy of calcium channel blockers
• Market Challenges
  • Adverse effects associated with calcium channel blockers

Porter's Five Forces: A Strategic Tool for Navigating the Calcium Channel Blockers Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Calcium Channel Blockers Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Calcium Channel Blockers Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Calcium Channel Blockers Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Calcium Channel Blockers Market

A detailed market share analysis in the Calcium Channel Blockers Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Calcium Channel Blockers Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Calcium Channel Blockers Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Calcium Channel Blockers Market

A strategic analysis of the Calcium Channel Blockers Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Calcium Channel Blockers Market, highlighting leading vendors and their innovative profiles. These include Apotex Inc., Astellas Pharma Inc., AstraZeneca PLC, Bausch Health Companies Inc., Bayer AG, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Company, Cadila Pharmaceuticals Limited, Daiichi Sankyo Company, Limited, Dr. Reddy's Laboratories Ltd., Glenmark Pharmaceuticals U.S. Inc., Hikma Pharmaceuticals PLC, INTAS PHARMACEUTICALS LTD., Kyowa Kirin Co., Ltd., Lupin Pharmaceuticals, Inc., Merck & Co., Inc., Novartis AG, OTSUKA PHARMACEUTICAL CO., LTD., Pfizer Inc., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Calcium Channel Blockers Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug Class, market is studied across Benzodiazepine, Dihydropyridine, and Phenylalkylamine.
• Based on End User, market is studied across Homecare, Hospitals, and Specialty Clinics.
• Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising incidences of low blood pressure worldwide
    • 5.1.1.2. Inclination toward early diagnosis and treatment of diseases
    • 5.1.1.3. Increasing awareness regarding low blood pressure treatments
  • 5.1.2. Restraints
    • 5.1.2.1. Product recall and volatility in raw material cost
  • 5.1.3. Opportunities
    • 5.1.3.1. Introduction of new generation calcium channel blockers
    • 5.1.3.2. Clinical trials to test the efficacy of calcium channel blockers
  • 5.1.4. Challenges
    • 5.1.4.1. Adverse effects associated with calcium channel blockers
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Calcium Channel Blockers Market, by Drug Class

• 6.1. Introduction
• 6.2. Benzodiazepine
• 6.3. Dihydropyridine
• 6.4. Phenylalkylamine

7. Calcium Channel Blockers Market, by End User

• 7.1. Introduction
• 7.2. Homecare
• 7.3. Hospitals
• 7.4. Specialty Clinics

8. Calcium Channel Blockers Market, by Distribution Channel

• 8.1. Introduction
• 8.2. Hospital Pharmacy
• 8.3. Online Pharmacy
• 8.4. Retail Pharmacy

9. Americas Calcium Channel Blockers Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Calcium Channel Blockers Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Calcium Channel Blockers Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Apotex Inc.
• 2. Astellas Pharma Inc.
• 3. AstraZeneca PLC
• 4. Bausch Health Companies Inc.
• 5. Bayer AG
• 6. Boehringer Ingelheim International GmbH
• 7. Bristol Myers Squibb Company
• 8. Cadila Pharmaceuticals Limited
• 9. Daiichi Sankyo Company, Limited
• 10. Dr. Reddy's Laboratories Ltd.
• 11. Glenmark Pharmaceuticals U.S. Inc.
• 12. Hikma Pharmaceuticals PLC
• 13. INTAS PHARMACEUTICALS LTD.
• 14. Kyowa Kirin Co., Ltd.
• 15. Lupin Pharmaceuticals, Inc.
• 16. Merck & Co., Inc.
• 17. Novartis AG
• 18. OTSUKA PHARMACEUTICAL CO., LTD.
• 19. Pfizer Inc.
• 20. Sanofi S.A.
• 21. Sun Pharmaceutical Industries Ltd.
• 22. Takeda Pharmaceutical Company Limited
• 23. Teva Pharmaceutical Industries Ltd.